Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23


Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.

Juergens RA, Mariano C, Jolivet J, Finn N, Rothenstein J, Reaume MN, Faghih A, Labbé C, Owen S, Shepherd FA, Villeneuve J, Romeyer F, Pettersson F, Butts C.

Curr Oncol. 2018 Dec;25(6):384-392. doi: 10.3747/co.25.4287. Epub 2018 Dec 1.


Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.

Gettinger S, Hellmann MD, Chow LQM, Borghaei H, Antonia S, Brahmer JR, Goldman JW, Gerber DE, Juergens RA, Shepherd FA, Laurie SA, Young TC, Li X, Geese WJ, Rizvi N.

J Thorac Oncol. 2018 Sep;13(9):1363-1372. doi: 10.1016/j.jtho.2018.05.015. Epub 2018 May 23.


Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.

Melosky B, Chu Q, Juergens RA, Leighl N, Ionescu D, Tsao MS, McLeod D, Hirsh V.

Cancer Treat Rev. 2018 Apr;65:65-77. doi: 10.1016/j.ctrv.2018.02.005. Epub 2018 Feb 22. Review.


Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective.

Cabanero M, Sangha R, Sheffield BS, Sukhai M, Pakkal M, Kamel-Reid S, Karsan A, Ionescu D, Juergens RA, Butts C, Tsao MS.

Curr Oncol. 2017 Apr;24(2):111-119. doi: 10.3747/co.24.3524. Epub 2017 Apr 27. Review.


Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.

Iafolla MAJ, Juergens RA.

Front Oncol. 2017 Apr 6;7:67. doi: 10.3389/fonc.2017.00067. eCollection 2017. Review.


Oncology care provider perspectives on exercise promotion in people with cancer: an examination of knowledge, practices, barriers, and facilitators.

Nadler M, Bainbridge D, Tomasone J, Cheifetz O, Juergens RA, Sussman J.

Support Care Cancer. 2017 Jul;25(7):2297-2304. doi: 10.1007/s00520-017-3640-9. Epub 2017 Mar 3.


Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.

Juergens RA, Bratman SV, Tsao MS, Laurie SA, Sara Kuruvilla M, Razak AR, Hansen AR.

Cancer Treat Rev. 2017 Mar;54:43-57. doi: 10.1016/j.ctrv.2017.01.003. Epub 2017 Jan 17. Review.


A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.

Crandall JP, Tahari AK, Juergens RA, Brahmer JR, Rudin CM, Esposito G, Subramaniam DS, Knopp MV, Hall NC, Gajwani P, Leal JP, Lodge MA, O JH, Gabrielson EW, Shankar LK, Wahl RL.

EJNMMI Res. 2017 Dec;7(1):8. doi: 10.1186/s13550-017-0258-3. Epub 2017 Jan 19.


Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ.

Lancet Oncol. 2017 Jan;18(1):31-41. doi: 10.1016/S1470-2045(16)30624-6. Epub 2016 Dec 5.


Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.

Leighl NB, Rizvi NA, de Lima LG Jr, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, Singh M, Steinberg J, Juergens RA, Gadgeel SM.

Clin Lung Cancer. 2017 Jan;18(1):34-42.e2. doi: 10.1016/j.cllc.2016.07.007. Epub 2016 Aug 8.


Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, Juergens RA, Laurie SA, Nathan FE, Shen Y, Harbison CT, Hellmann MD.

J Clin Oncol. 2016 Sep 1;34(25):2980-7. doi: 10.1200/JCO.2016.66.9929. Epub 2016 Jun 27.


Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia S.

J Clin Oncol. 2016 Sep 1;34(25):2969-79. doi: 10.1200/JCO.2016.66.9861. Epub 2016 Jun 27.


Multidisciplinary Influence on Care of Lung Cancer Patients at the Time of Diagnosis: a Patient Survey.

Yiu KC, Juergens RA, Swaminath A.

Clin Oncol (R Coll Radiol). 2016 Oct;28(10):667. doi: 10.1016/j.clon.2016.04.046. Epub 2016 May 24. No abstract available.


Imaging Biomarkers in Immunotherapy.

Juergens RA, Zukotynski KA, Singnurkar A, Snider DP, Valliant JF, Gulenchyn KY.

Biomark Cancer. 2016 Feb 25;8(Suppl 2):1-13. doi: 10.4137/BIC.S31805. eCollection 2016. Review.


Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.

Macaulay VM, Middleton MR, Eckhardt SG, Rudin CM, Juergens RA, Gedrich R, Gogov S, McCarthy S, Poondru S, Stephens AW, Gadgeel SM.

Clin Cancer Res. 2016 Jun 15;22(12):2897-907. doi: 10.1158/1078-0432.CCR-15-2218. Epub 2016 Feb 1.


Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.

Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, Tykodi SS, Easton K, Carvajal RD, Jones PA, Laird PW, Weisenberger DJ, Tsai S, Juergens RA, Topalian SL, Rudin CM, Brock MV, Pardoll D, Baylin SB.

Oncotarget. 2013 Nov;4(11):2067-79.


Aberrant epigenetic regulation: a central contributor to lung carcinogenesis and a new therapeutic target.

Juergens RA, Rudin CM.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e295. Review.


Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.

Rudin CM, Brahmer JR, Juergens RA, Hann CL, Ettinger DS, Sebree R, Smith R, Aftab BT, Huang P, Liu JO.

J Thorac Oncol. 2013 May;8(5):619-23. doi: 10.1097/JTO.0b013e31828c3950.


Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.

Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA, Herman JG, Baylin SB, Brock MV, Rudin CM.

Cancer Discov. 2011 Dec;1(7):598-607. doi: 10.1158/2159-8290.CD-11-0214. Epub 2011 Nov 9.


Bevacizumab in advanced lung cancer: in search of the right drug for the right patient.

Burns TF, Juergens RA.

Oncology (Williston Park). 2010 Nov 30;24(13):1223-4, 1226. No abstract available.


Combined modality therapy of esophageal cancer.

Juergens RA, Forastiere A.

J Natl Compr Canc Netw. 2008 Oct;6(9):851-60; quiz 861. Review.


Adjuvant treatment in non-small cell lung cancer: Where are we now?

Juergens RA, Brahmer JR.

J Natl Compr Canc Netw. 2006 Jul;4(6):595-600. Review.


Adjuvant therapy for resected non-small-cell lung cancer: past, present, and future.

Juergens RA, Brahmer JR.

Curr Oncol Rep. 2005 Jul;7(4):248-54. Review.


Supplemental Content

Loading ...
Support Center